Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of DMX-200 in focal segmental glomerulosclerosis (FSGS) on ARB therapy
2021-004174-64Phase 3Active
- Sponsor
- Dimerix
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing DMX-200 + ARB with Placebo + ARB (2 arms). Primary endpoints: Percent change in urine protein-to-creatinine ratio and eGFR slope. Started Dec 2021; status: active.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2021-004174-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004174-64.